



# ‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

Mark A. Jarosinski<sup>1</sup> · Balamurugan Dhayalan<sup>1</sup> · Nischay Rege<sup>2</sup> · Deepak Chatterjee<sup>1</sup> · Michael A. Weiss<sup>1,3,4</sup>

Received: 20 October 2020 / Accepted: 15 January 2021 / Published online: 12 March 2021  
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

## Abstract

Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper- or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulin-delivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such ‘smart’ systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimize mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based ‘closed-loop’ systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin’s conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.

**Keywords** Artificial pancreas · Glucose sensor · Glucose-responsive insulin · Glucose-responsive polymers · Hormone-receptor recognition · Review

## Abbreviations

CGM	Continuous glucose monitoring
ConA	Concanavalin A
FRI	Fructose-responsive insulin
GRI	Glucose-responsive insulin
IRT	Insulin replacement therapy
PBA	Phenylboronic acid
TIR	Time in range

## Introduction

Insulin replacement therapy (IRT) is essential for the treatment of type 1 diabetes mellitus and often required by patients with late-stage type 2 diabetes. Advances in diabetes technologies have been broadly motivated by the aim to link optimisation of IRT (including individualised glycaemic goals in type 2 diabetes [1, 2]) and healthcare outcomes [3–8]. During a typical 24 h period, patients on insulin therapy often exhibit episodes of hyperglycaemia or hypoglycaemia [9], despite individualised dosing regimens [10, 11] and the broad use of engineered basal and rapid-acting insulin analogues [12–14]. Indeed, glycaemic excursions outside the narrow blood glucose range classified as normoglycaemia (4.4–6.7 mmol/l) [15] are frequent despite strict adherence to dietary and lifestyle recommendations [16, 17]. These challenges have motivated innovation in ancillary technologies: formulation chemistry, protein engineering, glucose-sensing technologies and delivery devices [18, 19]. Integrating IRT with engineered mechanisms of feedback (whether at the level of protein, cell or device) represents a critical current frontier

✉ Michael A. Weiss  
weissma@iu.edu

<sup>1</sup> Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>2</sup> Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

<sup>3</sup> Department of Chemistry, Indiana University, Bloomington, IN, USA

<sup>4</sup> Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA

of innovation, with the overarching goal of fewer hyperglycaemic excursions and reduced time in hypoglycaemia (i.e. increased time in range [TIR]). TIR is a major issue, ever-present in the daily life of an individual with type 1 diabetes [20, 21] and in a subset of those with type 2 diabetes [22].

In this review we outline a range of glucose-responsive ('smart') approaches to control TIR and discuss the prospects for mechanism-based molecular design of intrinsic glucose-responsive insulin (GRI) analogues [23]. Such delivery systems or insulin analogues seek to optimise TIR by the combined approaches of increased engineering controls to deliver insulin therapeutics and the molecular design of new chemical entities. Like endogenous beta cells, such systems (broadly designated GRIs) would provide insulin activity proportionate to the metabolic state. Accordingly, the GRI concept has attracted the attention of the research community [24–27] and funders [28, 29] alike.

GRIs may be broadly classified as: (1) algorithm-based mechanical GRI systems (closed-loop delivery systems as an 'artificial pancreas') based on continuous glucose monitoring (CGM)-coupled insulin pumps [30]; (2) polymer-based systems, wherein insulin is encapsulated within a glucose-responsive polymeric matrix-based vesicle or hydrogel [31]; or (3) molecular GRI analogue systems, which involve the introduction of a glucose-sensitive motif to the insulin molecule or its formulation that, in either case, confers glucose-responsive changes to bioavailability or hormonal activity [32] (Fig. 1). We highlight potential synergies among these technologies as molecular GRIs may, in principle, be delivered via a closed-loop system (for further review, please see a related article in this special series by Boughton and Hovorka [33]). Cell-based therapies, which provide biological feedback regulation [34, 35], are beyond the scope of this review.

## Mechanical systems

**Closed-loop systems** Mechanical GRI systems [36] integrate: (1) CGM to provide real-time measurement of interstitial glucose concentration; (2) an insulin pump receiving CGM input; and (3) a control algorithm specifying the appropriate dose of insulin for minute-by-minute s.c. injection [11, 37, 38]. Although these systems promise to improve 24 h glycaemic control in diverse patient populations (including adults, adolescents and children), CGM-based measurements of interstitial glucose concentrations lag by ~20 min behind changes in blood glucose levels, complicating prediction of future glycaemic trends. Reliable prediction is important because a 'rapid-acting' insulin analogue (once injected) may require 20–40 min for absorption and, once in the blood stream, may exert biological effects lasting 3–4 h [39]. The robustness of current predictive algorithms is likely to be


enhanced by development of 'ultra-fast' pump insulin analogue formulations [40], such as Fiasp (Novo Nordisk) [41, 42], ultra-rapid lispro (URLi; known as Lyumjev in Europe; Eli Lilly) [43, 44], and respective reformulations of prandial analogues insulin, including insulin aspart (Pro<sup>B28</sup> → Asp) and insulin lispro (Pro<sup>B28</sup> → Lys and Lys<sup>B29</sup> → Pro) [45–47]. The progress of CGM along with automated real-time insulin titration and bolus calculators, has enabled initial regulatory approval of mechanical GRI systems [11].

**Dual-hormone pumps** To prevent or treat hypoglycaemia more effectively, bihormonal pumps have been developed to provide either insulin or its counter-regulatory hormone glucagon [48–53]. Dual-hormone algorithms trigger s.c. injections of a stabilised glucagon formulation based on trends in CGM readings predicting an impending hypoglycaemic excursion, thereby maintaining blood glucose levels within range more efficiently than conventional CGM-coupled insulin pumps [54, 55]; the extent of advantage and its clinical impact have been the subject of debate. Fibrillation-resistant formulations of glucagon or glucagon analogues would be required for practical bihormonal systems [56].

**Insulin stability in closed-loop systems** Ultra-miniaturisation of sensors and improved accuracy of pumps [36, 57, 58] have encouraged reconsideration of i.p. delivery of insulin via i.p. infusion devices [59, 60]. Implanted refillable pumps [61] have promised ultra-rapid pharmacokinetic dosing profiles of insulin with first-pass hepatic signalling in the portal circulation. These advantageous features have stimulated interest in novel i.p.-compatible insulin analogue formulations; desiderata include insulins with even more rapid onset of activity, shorter duration and greater formulation stability compared with the insulin therapeutics currently on the market.

Despite the above theoretical advantages and the convenience of long-term i.p. reservoirs of insulin (up to 3 months), catheter occlusion [62] remains a concern that has limited the feasibility of such systems in otherwise encouraging clinical trials [63]. Occlusions are often mediated by immunogenic and proinflammatory insulin-derived amyloid fibrils [64, 65]. Insulin instability and fibrillation can also occur within the pump reservoir to inactivate the hormone and provide seeds for further cycles of fibrillation.

Risk of insulin degradation in i.p. systems might be mitigated through design and development of ultra-stable, fibrillation-resistant analogues. Examples are provided by single-chain insulins (SCIs) containing a foreshortened C domain [66] and by two-chain insulin analogues containing an engineered non-canonical disulfide bridge between A- and B-chains [67–69] (Fig. 2). The altered topology (connectivity) of such analogues appears incompatible with cross-β assembly, the canonical core structure of an amyloid [70–72]. Their



**Fig. 1** Design strategy for intrinsic molecular GRIs. **(a)** Sequence of insulin showing A-chain and B-chain with typical sites of chemical modification underlined (Gly<sup>A1</sup> N-terminal and B-chain residues B27–B30) that affect pharmacokinetics and monosaccharide responsivity. Amino acid residues are labelled using their standard single letter codes. **(b)** Design scheme of monosaccharide-responsive insulin. The ribbon model of closed inactive insulin (T-state monomer) is shown (with a free glucose

molecule adjacent to it); the blue box highlights sites of chemical modification (red horseshoe shapes indicate glucose-binding element; green diamonds indicate internal diol). The envisioned glucose-regulated conformational cycle in which a monosaccharide acts as a competitive ligand to regulate a conformational switch between the closed state (inactive in absence of ligand) and the open state (active in presence of ligand) is illustrated. This figure is available as part of a [downloadable slideset](#)

topologies may, in principle, alter the signalling properties of the hormone. Insertion of non-canonical cystine B4–A10 (Fig. 2b), for example, is associated with anomalously prolonged duration of activity of insulin upon intravenous bolus injection in rat studies [67], an unfavourable property of a pump insulin, the safety of which relies on fast-on/fast-off pharmacodynamics. Clinical data are not available.


## Polymer-based GRI systems

Polymer-based technologies exploit sequestration of native or derivatised insulin within a matrix suitable for s.c. injection by directly integrating glucose-responsive components into delivery systems [73, 74]. The matrix, in principle, senses the glucose concentration and releases a proportional amount of insulin. Three classes of glucose-sensitive motifs have enabled such feedback: (1) glucose-binding proteins, a class that includes lectins, like concanavalin A (ConA); (2) glucose oxidase, an enzyme that catalyses oxidation of glucose to gluconic acid with release of a proton (hence lowering the pH); and (3) boronate-based chemistries, exemplified by phenylboronic acid (PBA; see below), which form reversible ester linkages with diol-containing molecules [75], including glucose [76]. In addition to these categories, an innovative

recent technology envisions endogenous biological systems (e.g., the mannose receptor and even components of the erythrocyte) as a ‘smart’ matrix-based insulin delivery system [77, 78].

**Insulin–lectin complexes** More than 40 years ago, Brownlee and Cerami pioneered a model GRI system: glycosylated insulin complexed with ConA [24, 79]. This complex was designed to sequester insulin in the s.c. space during normoglycaemia and release the hormone during hyperglycaemia via competition with ambient glucose molecules (Fig. 3b). Although the strategy was successful *in vitro*, its competitive set point was above the range of typical hyperglycaemic concentrations [79]. ConA’s immunogenicity and mitogenicity might limit clinical translation [80, 81].

**Glucose-responsive polymers** Advances in materials science have enabled design of diverse candidate polymer-based GRI systems. These were based on initial observations of Lorand and Edwards [75] that boronic acids react reversibly with vicinal (1,2-) diols (like those that occur naturally in carbohydrates and catechol); their reaction yields boronate esters. Norrild and Eggert first provided NMR evidence that binding of PBA to D-glucose is primarily mediated by the  $\alpha$ -D -glucopyranose conformer (Fig. 4) [76]. Subsequently,



**Fig. 2** Ultra-stable insulin analogues. (a) Single-chain insulin (SCI) analogues exhibit native-like A and B domains (green and blue, respectively) with three native disulfide bridges (yellow). A foreshortened C-domain (5–8 residues; orange) connects the C-terminal B-chain  $\beta$ -strand (magenta) to the A-chain N-terminus. A favourable C-domain sequence can dampen conformational flexibility, augment thermodynamic stability and protect from fibrillation [66]. Protein Data Bank (PDB) ID: 2LWZ ([www.rcsb.org/](http://www.rcsb.org/); accessed: 1 February 2021). Figure adapted from [145]

with permission from Wolters Kluwer Health, Inc. (b, c) Ultra-stable two-chain insulin analogues with engineered fourth disulfide bridges. Crystal structure of the four-disulfide (4SS)-insulin analogues containing a disulfide bond in (b) position B4–A10 (PDB ID: 4EFX) [67] and (c) position B22–A22 (PDB ID: 6TYH) [69]. The disulfide bonds (shown in yellow) and labelled (yellow boxes). Images were created with PyMOL (<https://pymol.org/2/>; accessed: 1 February 2021). This figure is available as part of a [downloadable slideset](#)

Wang's group [82, 83] described a mechanism/mechanisms of binding between diols and boronic acids (reviewed by Joop A. Peters in relation to monosaccharides [84]). Such systems envisaged encapsulation of insulin within polymeric matrices to form a 'smart' s.c. depot. The set points of chemical equilibrium-based glucose-recognition technologies (relative to enzyme- or protein-based schemes) may be more amenable to optimisation than ConA systems were found to be.

Polymer-based GRIs can, in principle, employ a variety of encapsulation chemistries, including polyethylene glycol (PEF), poly(*N*-vinyl-pyrrolidone) and succinyl-amidophenyl-glucopyranoside [31, 74, 85]. Whereas the matrices are impermeable to insulin during normoglycaemic or hypoglycaemic conditions, their permeability may increase as a result of physical changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration. Examples include matrices co-derivatised with PBA, other boronic acids [86–88] and dot-immobilised glucose ester-based crosslinks [74, 85, 89].

Immobilised glucose-binding proteins and enzymes may also be integrated with glucose-modified polymers [77, 90]. Of particular interest, glucose oxidase has been encapsulated in matrices that are chemically sensitive to  $H_2O_2$ , hypoxia or decreases in local pH. Unlike PBA and non-enzymatic glucose-binding-protein-based technologies, polymeric matrices in glucose oxidase-based systems exploit its catalytic activity to increase the polymer's water permeability and, so, regulate hormone release [91, 92] (for review, see Wang et al [73]).


Polymer-based GRI technologies are challenged by limited particle stability [93, 94], lag times and suboptimal insulin-response rates leading to hyperglycaemic or hypoglycaemic excursions. Addressing these limitations has encountered a catch-22: sensitising matrices to hyperglycaemia, for example, can limit their ability to attenuate insulin release at low

glucose concentrations. The latter problem can be exacerbated by matrix degradation, in principle raising the risk of severe hypoglycaemic episodes in patients due to bolus over-delivery [95, 96].

## Intrinsic GRI systems

Intrinsic (or unimolecular) GRIs define a novel class of analogues wherein the modified hormone itself confers glucose-dependent activity or bioavailability. Initial candidate technologies relied on sequestration of active insulin hormone within the s.c. space or within the bloodstream (as inactive complexes) with enhanced release or activation only during hyperglycaemia. Recent bio-inspired advances exploit specific endogenous features of the s.c. space, potential hormone-carrier proteins or cellular clearance systems. Although these elegant strategies remain in the early stages of development, their simplicity, convenience and potential cost-effectiveness make them an attractive target of ongoing research. Because standard insulin products are becoming a commodity in the pharmaceutical industry, clinical introduction of chemically modified insulins that are glucose responsive will likely require detailed analysis of cost-effectiveness despite their elegance.

**Insulin fusion proteins** A pioneering approach employed an insulin–glucose oxidase fusion molecule [97]. A cysteine-based linkage was broken as the enzyme oxidised glucose. Although proof of principle was obtained *in vitro*, the low  $K_m$  of the enzyme for glucose led to liberation of the hormone under hypoglycaemic, as well as hyperglycaemic conditions [97]. In addition, release of  $H_2O_2$  by glucose oxidase (as a byproduct of glucose oxidation) and generation of reactive oxygen species (ROS) could cause tissue injury. In a




**Fig. 3** GRI-inspired derivatisation of insulin. **(a)** Insulin contains two peptide chains (designated ‘A’ and ‘B’) connected by two disulfide linkages (cystines A7–B7 and A20–B19). **(b)** Brownlee and Cerami [24, 79] created a molecular GRI by coupling saccharides to the N-termini of one or both polypeptide chains of insulin (shown as red circles in **a**). The analogues (grey ovals) were bound to ConA (red star) before administration in rats. ConA was expected to sequester the modified insulin in the s.c. space under euglycaemic conditions, but allow its liberation following competitive binding of ambient glucose (blue hexagons) during hyperglycaemia [24, 79]. **(c)** A GRI system employing insulin glargine (purple ovals; its three amino acid substitutions denoted as purple circles in **a**) was co-injected with glucose oxidase (GoD; red polygon), which was expected to lower local pH by oxidising glucose to gluconic acid (dark blue circles) at a rate proportional to the glycaemic state, thereby increasing the solubility and, hence, pH-dependent bioavailability of the analogue. **(d–f)** A number of groups have modified the  $\epsilon$ -amino group of Lys<sup>B29</sup> of the insulin molecule with PBA derivatives (green hexagons) to

create candidate GRI systems. **(d)** Hoeg-Jensen et al [32] directly coupled Lys<sup>B29</sup> with PBA derivatives, enabling binding to diol-containing polymer carriers (orange rectangles with red circles) in a glucose-dependent fashion [32]. **(e)** The same group also derivatised residue B29 with a molecule containing a PBA and a polyol group (black lines with red circles), leading to multi-hexameric complexes in vitro that could dissociate in a glucose-dependent fashion [110]. **(f)** Chou and colleagues [112] created a GRI that contained a PBA derivative coupled via a fatty-acyl linker (black jagged line) to Lys<sup>B29</sup>. They hypothesised that this analogue would bind to albumin (blue oval) below a threshold level of blood glucose, being liberated during hyperglycaemia as glucose-modified PBA–insulin, which was envisioned to have decreased affinity for albumin; however, the GRI-responsive mechanism of lower affinity of the glucose-modified PBA–insulin for albumin was not confirmed [112]. Figure adapted from [145] with permission from Wolters Kluwer Health, Inc. This figure is available as part of a [downloadable slideset](#)

complementary approach, glucose oxidase-dependent changes in s.c. pH were exploited to modulate the solubility (and, hence, rate of absorption) of insulin glargine, the isoelectric point-shifted active component of Lantus (Sanofi) [98]. Because this basal analogue is insoluble at neutral pH but soluble under acidic conditions, glucose oxidase-mediated acidification (via production of gluconic acid), in principle,

enhances bioavailability [99] (Fig. 3c). Although in vitro and pilot animal studies appear promising, clinical data has not yet been obtained [100].

**Biology-inspired GRI systems** An attractive frontier of GRI engineering takes advantage of an endogenous biological system, ‘hijacked’ in its native form to provide an active



**Fig. 4** Biomimetic and chemical strategies to bind glucose vs fructose. Selective but reversible capture strategies exploit different molecular features and reactivity in conformational equilibria in water at pH 7.4 between saccharides, such as D-fructose and D-glucose conformations. D-Fructose populates  $\beta$ -D-fructopyranose, D-fructosyl ketone and  $\beta$ -D-fructofuranose (per cent population: 61%, 0.8% and 25%, respectively) and D-glucose populates  $\beta$ -D-glucopyranose, D-glucosyl aldehyde and  $\alpha$ -D-glucofuranose (per cent population: 65%, 0.0024% and 0.14%, respectively) (data from [75]). **(a)** The biomimetic approach has achieved selective binding of  $\beta$ -D-glucopyranose over  $\beta$ -D-fructopyranose (association constant [ $K_a$ ]  $\sim 18,000 \text{ M}^{-1}$  and  $K_a \sim 51 \text{ M}^{-1}$ , respectively). This is owing to the all equatorial polar hydroxy groups in  $\beta$ -D-glucopyranose (shown in blue) that form specific hydrogen bonds with the preorganised urea-based cage elements and the dual phenyl groups in the biomimetic receptor complex (shown in red and blue, respectively), which make apolar hydrophobic contacts with the glucopyranose ring with solubilising groups (shown in green) [146]. Neither D-fructose nor other saccharides accommodate these requirements for interaction with the biomimetic receptor complex [125]. **(b)** Jensen and colleagues [114] demonstrated a novel chemical approach to D-glucose selectivity by exploiting its open chain, acyclic D-glucosyl aldehyde. A series of masked cleavable hydrazones or thiazolidines were tuned for aldehyde reactivity (carbonyl

groups shown in blue). These GRI designs relied on hydrolysis of a hydrazone or thiazolidine linker that was covalently attached to insulin at one end and C18 fatty acid at the other. On hydrolysis, D-glucosyl aldehyde reacts with the free unmasked linker-moiety, resulting in a shift of equilibrium towards a free active insulin analogue. Increasing concentrations of glucose (from normoglycaemia to hyperglycaemia) are proposed to drive this shift. In contrast, D-fructose's acyclic form (D-fructosyl ketone [shown in blue]) is reactive to the unmasked linkers but not generally found in the body [114]. **(c)** PBAs bind most strongly to aligned 1,2-diol elements, such as those found in  $\beta$ -D-fructofuranose; respective conformational equilibria, thus, favour selective binding to fructose [84]. The acidity of PBAs is also known to affect diol reactivity, with vicinal diols known to produce boronate esters [75, 83], as illustrated by the  $\alpha$ -D-glucofuranose/boronate ester in the figure. Key *cis*-hydroxyl groups are coloured red. D-Fructopyranose,  $\beta$ -D-fructofuranose,  $\beta$ -D-glucopyranose and  $\alpha$ -D-glucofuranose images adapted from [108], published by The Royal Society of Chemistry under the terms of the Creative Commons Attribution 3.0 Unported License (<https://creativecommons.org/licenses/by/3.0/>). Biomimetic receptor complex image adapted from [146] by permission from Springer Nature, ©2018. This figure is available as part of a [downloadable slideset](#)

component of a glucose-dependent regulatory scheme. Such an approach was developed by Merck, based on competitive

clearance of a saccharide-modified insulin by the endogenous mannose receptor [101, 102]. The saccharide adduct presented

terminal mannose moieties and so provided a substrate for clearance by the ubiquitous mannose receptor system. The essential idea envisioned rapid clearance of the modified insulin under conditions of hypoglycaemia but slow clearance under conditions of hyperglycaemia due to low-affinity binding of glucose to (and, hence, competition at) the mannose receptor. The glucose-dependent differences in rates of clearance, although not large, were sufficient to provide partial protection from hypoglycaemia relative to the same dose of an unmodified insulin. Although animal-based and pilot clinical studies were pursued, this approach is no longer under development. These challenges to create a modified insulin with an improved therapeutic index that enables tighter glycaemic control with a reduced risk for hypoglycaemia, as well as the challenges of translating in vivo animal models and data for application in humans, highlight the importance of developing better in silico GRI modelling in the developmental pipeline [23, 103–105].

**PBA-modified insulin derivatives** PBA is a diol-binding element that is able to sense carbohydrates [106–108]. A PBA-modified insulin derivative was first described as a potential intrinsic GRI by Hoeg-Jensen et al [32]. This work established that PBA could be coupled to the insulin B29 position without affecting its biological activity, in turn enabling the analogue to bind diol-containing sequestering agents (Fig. 3). The investigators further demonstrated that a modified insulin carrying both a PBA and a polyol group attached to the Lys<sup>B29</sup> sidechain could form high molecular weight multimeric complexes that dissociate under control by D-sorbitol or D-glucose (Fig. 3e) [109, 110]. A sidechain glutamic acid linker was required for in vitro activity, as is the case for insulin degludec, a second-generation basal acylated insulin [111]. To our knowledge, no in vivo results have been described.

Novel use of a PBA-based GRI was described by Chou and colleagues [112] who employed an acylated insulin analogue (insulin detemir) in which myristic acid was coupled onto lysine (Lys<sup>B29</sup>) to mediate binding to serum albumin and, so, provide a long-lived circulating depot of insulin. The hydrocarbon acyl tag was further derivatised with PBA so that its affinity for albumin might be glucose responsive. The essential idea thus envisioned albumin as a glucose-dependent carrier, similar, in spirit, to the reported use of erythrocyte membranes as glucose-dependent carriers [77, 113]. Although this goal was not achieved in vitro with this analogue (i.e. the albumin-binding properties of the analogues were not glucose-dependent), several such candidate GRI analogues exhibited glucose-responsive biological activity in a peritoneal glucose-infusion assay in mice [73].

In a similar manner to the above, Jensen and colleagues [114] took advantage of albumin binding as a plasma depot to demonstrate novel GRI activity acceleration, which was

mediated by aldehyde-responsive capture of released insulin. The strategy biased for glucose reactivity over fructose by virtue of aldehyde capture based on the increased reactivity of acyclic glucosyl aldehyde over fructosyl ketone and the fact that fasting glucose concentrations are about >1000-fold greater than those of fructose (Fig. 4) [114]. In the same study [114], in glucose clamp models, some insulin analogues demonstrated GRI activity, but their in vitro hydrolysis rates were >6 h, suggesting that lag time might be an issue.

**Glucose-regulated conformational switches** A reversible conformational cycle between active and inactive states of insulin may, in principle, be regulated by a ligand, such as glucose (Fig. 1b). A new avenue for molecular GRI design was inspired by crystallographic and cryogenic electron microscopy (cryo-EM) studies of insulin bound to fragments of the insulin receptor [115, 116], including the intact ectodomain [117, 118]. Such studies revealed a major change in the conformation of insulin on receptor binding in which the hormone ‘opens’ with detachment of the C-terminal B-chain segment; this enables intimate contact between the N-terminal A-chain  $\alpha$ -helix and the receptor complex [117, 118].

It may be possible to exploit the mechanism of insulin–insulin receptor binding and signalling to design a glucose-dependent conformational switch, such that binding of the modified insulin to the insulin receptor is impaired under hypoglycaemic conditions. A glucose-displaceable bridge between a glucose-binding element attached to one position in the insulin molecule and an internal ligand (such as a diol or saccharide) may, in principle, be placed at any pair of sites, such that the ‘closed state’ is inactive and the ‘open state’ is active. Proof of principle was recently provided in studies of a fructose-responsive insulin (FRI), in which *meta*-fluoro-PBA was attached to the A-chain N-terminus, and an aromatic diol group was attached to the  $\epsilon$ -amino group of Lys<sup>B28</sup> to provide an internal tether between the A- and B-chains (see ‘open, active’ form in Fig. 1b) [119]. Whilst the baseline activity of this analogue was low, near-native activity (as assessed in studies of the liver-derived cell line HepG2) was restored by 50 mmol/l fructose, but not by 50 mmol/l glucose [119].

The binding preference of PBA and its derivatives for fructose (relative to glucose) reflects their respective conformational equilibria and, in particular, the subpopulation of conformers displaying *cis*-1,2-diols that have hydroxyl groups that are oriented *syn*-periplanar (same side) for joint presentation to the boronic acid (Fig. 4c) [108]. Such alignment depends on the conformational equilibrium of a monosaccharide, as is observed in the  $\beta$ -D-fructofuranose form (Fig. 4c). Because the analogous conformation of glucose ( $\alpha$ -D-glucopyranose; Fig. 4c) is >100-fold less populated compared with  $\beta$ -D-fructofuranose at equilibrium in solution [84, 120], binding of PBAs to fructose is significantly favoured.


Improved glucose-binding elements will be required to extend the FRI proof-of-principle results to obtain bona fide GRIs. A chemical diversity of candidate boronate-based glucose sensors has been described [73, 82, 121–124], as well as non-boronate-based chemistries [125–127]. In addition, the above FRI's bridge between the A-chain N-terminus and B-chain C-terminus follows naturally from the hormone's mechanism of insulin receptor binding [116], but a wide variety of bridges might exhibit analogous glucose-responsive properties. Such design options promise an opportunity to co-optimize other GRI molecular features, including stability and immunogenicity.

To define potential non-canonical pairs of conformational switch sites suitable for GRI design, DiMarchi and colleagues [128] undertook a systematic survey of fourth disulfide bridges in an insulin analogue (*des*-[B29,B30]-Lys<sup>B28</sup>-insulin; 'DesDi' [129]). Whereas previous efforts to engineer additional disulfide bridges into insulin were motivated by stability [67–69], this study's emphasis was on differences in insulin receptor binding on closure of the fourth bridge. Six such pairs of putative switch sites were identified based on this functional criterion (Fig. 5). These pairs are distant in the native structure of insulin; formation of the engineered disulfide bridge (forced by selective chemical tactics) presumably distorts the conformation of the hormone, including its insulin receptor-binding

surface. Predicted distances between the unpaired cysteines in the framework of native insulin (T state) are given in Fig. 5 and reported as interatomic distances.

To visualise these novel analogues on closure of the non-native disulfide bridge, we undertook molecular modelling of the six constrained insulin analogues based on distance-geometry and restrained molecular dynamics. A baseline set of restraints was provided by prior NMR analysis of engineered insulin monomers [130, 131]. Of such fourth disulfide bridges, only cystine A0–B26 (Fig. 6c) could be accommodated within a native-like protein conformation (Fig. 7). A glucose-displaceable tether between amino acid residues A0 and B26 would, thus, be analogous to the fructose-regulated switch described above [119].


In the other five cases, formation of the fourth disulfide seems to require partial unfolding of the protein, perturbing one or more  $\alpha$ -helical elements (Fig. 6a, b, d–f); these distortions are incompatible with the structure of the primary insulin-binding site in the insulin receptor. For example, imposing cystines A8–B10 or A14–B10 in our modelling (Fig. 6d, e) distorted the central B-chain  $\alpha$ -helix and N-terminal A-chain  $\alpha$ -helix, key insulin receptor-binding elements [116]. Displacement of such aberrant bridges by glucose would presumably relieve the distortion and, so, restore activity. A rational path towards switchable intrinsic GRIs, based on strained disulfide



**Fig. 5** Search for non-canonical disulfide-based conformational switch sites as designed by Brunel et al [128]. Location of fourth disulfide bonds and their predicted interatomic distances (indicated by dashed lines between sulphur atoms [yellow spheres]); predicted interatomic distances shown in angstroms [Å] in the insulin monomer (crystallographic T state; Protein Data Bank [PDB] ID: 4INS [www.rcsb.org/; accessed: 1 February 2021]). The disulfide pairs in (a–f) were chosen based on their reported insulin receptor-binding activity, the open:closed ratio of which

was >100; they were associated with >100-fold decrease in activity on fourth disulfide-bond formation. The pairs are: (a) A0–B17; (b) A0–B22; (c) A0–B26; (d) A8–B10; (e) A14–B10; and (f) B10–B22. Sulphur atoms are shown in the substituted cysteines. Native disulfide bonds are shown as yellow lines; A-chain shown in green and B-chain in blue. Data were taken from [128]; images were created with PyMOL (https://pymol.org/2/; accessed: 1 February 2021). This figure is available as part of a downloadable slideset






**Fig. 6** Structural distortions among putative disulfide switch analogues [128] predicted on closure of a fourth disulfide bridge involve (a) cystine A0–B17, (b) cystine A0–B22, (c) cystine A0–B26, (d) cystine A8–B10, (e) cystine A14–B10 and (f) cystine B10–B22. A0 represents N-terminal extension of the A-chain by cystine. Only the model in (c) contains native  $\alpha$ -helical segments and a native-like tertiary structure; the other five models are remarkable for segmental unfolding of helical segments and distortion of helix–helix orientations. Models were calculated using Xplor-NIH (<https://nmr.cit.nih.gov/xplor-nih/>; accessed: 1 February 2021), based on distant restraints ( $\sim 750$  per model) derived from NMR

analysis of an engineered insulin monomer (Protein Data Bank [PDB] ID: 2JMN [[www.rcsb.org/](http://www.rcsb.org/); accessed: 1 February 2021]; [147]). Specific subsets of native distance restraints were removed to enable the designated additional disulfide bridge to be formed; distance restraints were omitted involving residues in: B9–B22 (a, b); B25–B30 and A0–A3 (c); B9–B16 and A2–A9 (d); A11–A16 and B9–B16 (e); and B9–B22 (f). Representative models were visualised and analysed using PyMOL (<https://pymol.org/2/>; accessed: 1 February 2021). A-chain shown in green and B-chain in blue. This figure is available as part of a [downloadable slideset](#)

engineering, was envisaged by DiMarchi and colleagues [128]. It would be of future interest to probe the structures and stabilities of these strained analogues, whether they contain cystine or reversible glucose-displaceable tethers. We anticipate that the set point for glucose displacement would be modulated by the degree of conformational strain.

## Clinical significance and conclusions

The centennial of the discovery of insulin marks a time of continuing innovation in insulin technologies. Even as the events leading to insulin discovery in Toronto in 1921 are celebrated as a landmark in molecular medicine, a comprehensive history recognises not only the contributions of Frederick



**Fig. 7** Mechanism of insulin–insulin receptor binding excludes certain engineered disulfide bridges. (a) Co-crystal structure of wild-type insulin bound to the micro-receptor ( $\mu$ IR) (Protein Data Bank [PDB] ID: 4OGA [[www.rcsb.org/](http://www.rcsb.org/); accessed: 1 February 2021]). Upon insulin binding to its receptor, the B-chain C-terminus moves away from A-chain, giving way to the  $\alpha$ -CT domain. (b) A0–B26 three-disulfide (3SS) insulin monomer bound to the  $\mu$ IR. The location of sulphur atoms in the fourth cysteine pairs is shown. (c) Modelled structure of four-disulfide (4SS) insulin

(A0–B26; see Fig. 6c) bound to the  $\mu$ IR. If the normal mode of binding takes place, the fourth A0–B26 disulfide bridge hinders the opening of the B-chain and causes a steric clash with the  $\alpha$ -CT domain. Images were created with PyMOL (<https://pymol.org/2/>; accessed: 1 February 2021). L1 domain shown as a pale cyan surface;  $\alpha$ -chain of carboxyl terminal ( $\alpha$ -CT) domain shown in magenta; insulin A-chain shown in green and B-chain in blue; sulphur atoms shown as yellow sphere. This figure is available as part of a [downloadable slideset](#)

Banting, Charles Best, James B. Collip and John J. R. Macleod, but also the key insights and advances made by others in the preceding five decades, beginning with Oskar Minkowski and Joseph von Mering (Germany) and continuing with Étienne Lancereaux (France), Nicolae C. Paulescu (Romania) and Israel Kleiner (USA) [132].

The present review highlights a vibrant frontier of insulin technologies. Whereas closed-loop systems have recently become a clinical reality [133–135], polymer-based and intrinsic GRIs promise to enhance the safety and efficacy of IRT. In addition to the elegance of the associated chemistries and macromolecular structures, ongoing research has a compelling clinical motivation: to enhance the health and quality of life of patients with type 1 diabetes and of patients with type 2 diabetes refractory to oral therapy—and with less burden on patients [136]. To bridge the valley between basic science and clinical applications, in silico simulations of animal physiology and human patients are likely to provide key guidance [23, 103–105].

All three classes of GRI technologies considered here, namely closed-loop delivery (as an ‘artificial pancreas’), polymer-based systems and molecular GRI analogue systems, seek to achieve optimal TIR. Standard IRT faces a trade-off: on the one hand, strict glycaemic control has been shown to retard or prevent microvascular complications in type 1 diabetes [6] and is likely to be beneficial in early stages of type 2 diabetes [137–139] but, on the other hand, aggressive glycaemic targets increase the acute and long-term risks of hypoglycaemia [10, 140–143]. Whereas CGM pump-based GRIs presently employ the most mature component technologies, recent innovations in matrix-based and unimolecular GRIs suggest promising routes towards safe and effective approximation of pancreatic beta cell function. We anticipate continuing progress in the coming years to reduce the burden of diabetes. Given the balance of price and access to new therapeutics (especially derivatised insulin analogues [144]) and the high human and economic costs of long-term diabetes complications, such innovative technologies are likely to be cost-effective when considering the integrated impact on society.

**Supplementary Information** The online version contains a slideset of the figures for download available at <https://doi.org/10.1007/s00125-021-05422-6>.

**Acknowledgements** We thank F. Ismail-Beigi (Case Western Reserve University, Cleveland, OH, USA), R. DiMarchi (Indiana University, Bloomington, IN, USA), M. D. Michael (Thermalin, Inc., Cleveland, OH, USA) and N. B. Phillips (Case Western Reserve University, Cleveland, OH, USA) for helpful discussions.

**Funding** Work in the authors’ laboratories is supported by the JDRF, the Leon M. and Harry B. Helmsley Charitable Trust and NIH R01 grants DK040949 and DK127761 (to MAW).

**Authors’ relationships and activities** MAW is Chief Innovation Officer of Thermalin, Inc. (Waban, MA, USA) in which he has equity. All the other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

**Contribution statement** All authors conceptualised the contents, revised the article critically for important intellectual content and approved this manuscript. MAW oversaw preparation of the manuscript and wrote the first draft.

## References

- Ismail-Beigi F (2011) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial - clinical implications. *Clin Chem* 57: 261–263. <https://doi.org/10.1373/clinchem.2010.148288>
- Ismail-Beigi F (2012) Glycemic management of type 2 diabetes mellitus. *N Engl J Med* 366(14):1319–1327. <https://doi.org/10.1056/NEJMcp1013127>
- The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329(14):977–986. <https://doi.org/10.1056/nejm199309303291401>
- Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 353(25):2643–2653. <https://doi.org/10.1056/NEJMoa052187>
- Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. *Am J Med* 123(3):S3–S11. <https://doi.org/10.1016/j.amjmed.2009.12.004>
- Nathan DM, Group DER (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care* 37(1):9–16
- Hayward RA, Reaven PD, Wiitala WL et al (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 372(23):2197–2206. <https://doi.org/10.1056/NEJMoa1414266>
- Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, DCCT/EDIC Research Group (2019) Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. *Diabetes Care* 42(7):1284–1289. <https://doi.org/10.2337/dc18-1613>
- Campbell MD, Walker M, Bracken RM et al (2015) Insulin therapy and dietary adjustments to normalize glycemia and prevent nocturnal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. *BMJ Open Diabetes Res Care* 3(1): e000085. <https://doi.org/10.1136/bmjdr-2015-000085>
- Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. *Ann Intern Med* 154(8):554–559. <https://doi.org/10.1059/0003-4819-154-8-201104190-00007>
- Nimri R, Battelino T, Laffel LM et al (2020) Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. *Nat Med* 26(9): 1380–1384. <https://doi.org/10.1038/s41591-020-1045-7>
- Vajo Z, Fawcett J, Duckworth WC (2001) Recombinant DNA technology in the treatment of diabetes: insulin analogs. *Endocr Rev* 22:706–717. <https://doi.org/10.1210/edrv.22.5.0442>
- Hartman I (2008) Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. *Clin Med Res* 6(2):54–67. <https://doi.org/10.3121/cmr.2008.793>
- Tibaldi JM (2014) Evolution of insulin: from human to analog. *Am J Med* 127(10 Suppl):S25–S38. <https://doi.org/10.1016/j.amjmed.2014.07.005>
- Petznick A (2011) Insulin management of type 2 diabetes mellitus. *Am Fam Physician* 84(2):183–190

16. Dandona P (2017) Minimizing glycemic fluctuations in patients with type 2 diabetes: approaches and importance. *Diabetes Technol Therap* 19(9):498–506. <https://doi.org/10.1089/dia.2016.0372>
17. Chehregosha H, Khamseh ME, Malek M, Hosseinpah F, Ismail-Beigi F (2019) A view beyond HbA1c: role of continuous glucose monitoring. *Diabetes Ther* 10(3):853–863. <https://doi.org/10.1007/s13300-019-0619-1>
18. Grant AK, Golden L (2019) Technological advancements in the management of type 2 diabetes. *Curr Diab Rep* 19(12):163. <https://doi.org/10.1007/s11892-019-1278-3>
19. Zimmerman C, Albanese-O'Neill A, Haller MJ (2019) Advances in type 1 diabetes technology over the last decade. *Eur Endocrin* 15(2):70–76. <https://doi.org/10.17925/ee.2019.15.2.70>
20. Yu S, Fu AZ, Engel SS, Shankar RR, Radican L (2016) Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus. *Curr Med Res Opin* 32(8):1409–1416. <https://doi.org/10.1080/03007995.2016.1176017>
21. Martyn-Nemeth P, Quinn L, Penckofer S, Park C, Hofer V, Burke L (2017) Fear of hypoglycemia: influence on glycemic variability and self-management behavior in young adults with type 1 diabetes. *J Diabetes Complicat* 31(4):735–741. <https://doi.org/10.1016/j.jdiacomp.2016.12.015>
22. Lipska KJ, Warton EM, Huang ES et al (2013) HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. *Diabetes Care* 36(11):3535–3542. <https://doi.org/10.2337/dc13-0610>
23. Bakh NA, Cortinas AB, Weiss MA et al (2017) Glucose-responsive insulin by molecular and physical design. *Nat Chem* 9(10):937. <https://doi.org/10.1038/nchem.2857>
24. Brownlee M, Cerami A (1979) A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. *Science* 206(4423):1190–1191. <https://doi.org/10.1126/science.505005>
25. Zaykov AN, Mayer JP, DiMarchi RD (2016) Pursuit of a perfect insulin. *Nat Rev Drug Discov* 15(6):425–439. <https://doi.org/10.1038/nrd.2015.36>
26. Hoeg-Jensen T (2020) Glucose-sensitive insulin. *Mol Metab* 10:1107. <https://doi.org/10.1016/j.molmet.2020.101107>
27. Disotuar MM, Chen D, Lin N-P, Chou DH-C (2020) Glucose-responsive insulin through bioconjugation approaches. *J Diabetes Sci Technol* 14(2):198–203. <https://doi.org/10.1177/1932296819854105>
28. NIDDK (2011) Advances and emerging opportunities in diabetes research: a Strategic Planning report of the Diabetes Mellitus Interagency Coordinating Committee. Available from: [www.niddk.nih.gov/about-niddk/strategic-plans-reports/advances-emerging-opportunities-diabetes-research-strategic-planning-report](http://www.niddk.nih.gov/about-niddk/strategic-plans-reports/advances-emerging-opportunities-diabetes-research-strategic-planning-report). Accessed 31 Jan 2021
29. Insel RA, Deecher DC, Brewer J (2012) Juvenile Diabetes Research Foundation: mission, strategy, and priorities. *Diabetes* 61(1):30–35
30. Halvorson M, Carpenter S, Kaiserman K, Kaufman FR (2007) A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump. *J Ped* 150(1):103–105. e101. <https://doi.org/10.1016/j.jpeds.2006.08.069>
31. Ravaine V, Ancla C, Catargi B (2008) Chemically controlled closed-loop insulin delivery. *J Control Release* 132(1):2–11. <https://doi.org/10.1016/j.jconrel.2008.08.009>
32. Hoeg-Jensen T, Ridderberg S, Havelund S et al (2005) Insulins with built-in glucose sensors for glucose responsive insulin release. *J Pept Sci* 11(6):339–346. <https://doi.org/10.1002/psc.624>
33. Boughton CK, Hovorka R (2021) New closed-loop insulin systems. *Diabetologia*. <https://doi.org/10.1007/s00125-021-05391-w>
34. Vegas AJ, Veisoh O, Gürtler M et al (2016) Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. *Nat Med* 22(3):306. <https://doi.org/10.1038/nm.4030>
35. Chen Z, Hu Q, Gu Z (2018) Leveraging engineering of cells for drug delivery. *Acc Chem Res* 51(3):668–677. <https://doi.org/10.1021/acs.accounts.7b00526>
36. Thabit H, Hovorka R (2016) Coming of age: the artificial pancreas for type 1 diabetes. *Diabetologia* 59(9):1795–1805. <https://doi.org/10.1007/s00125-016-4022-4>
37. Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. *Diabetes Technol Therap* 19(3):155–163. <https://doi.org/10.1089/dia.2016.0421>
38. Hanaire H, Franc S, Borot S et al (2020) Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. *Diabetes Obes Metab* 22(3):324–334. <https://doi.org/10.1111/dom.13898>
39. Genuth SM (1972) Metabolic clearance of insulin in man. *Diabetes* 21(10):1003–1012. <https://doi.org/10.2337/diab.21.10.1003>
40. Breton M, Farret A, Bruttomesso D et al (2012) Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. *Diabetes* 61(9):2230–2237. <https://doi.org/10.2337/db11-1445>
41. Cypriak K, Wyreńska-Niewęgłowska A (2018) New faster-acting insulin Fiasp®—do we need a new meal-time insulin? *Clin Diabetol* 7(6):282–286
42. Majdpour D, Yale J-F, Legault L et al (2020) 10-novel fully automated Fiasp-plus-pramlintide artificial pancreas for type 1 diabetes: randomized controlled trial. *Can J Diabetes* 44(7):S4–S5. <https://doi.org/10.1016/j.cjcd.2020.08.014>
43. Linnebjerg H, Zhang Q, LaBell E et al (2020) Pharmacokinetics and glucodynamics of ultra rapid Lispro (URLi) versus Humalog® (Lispro) in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. *Clin Pharm* 59(12):1589–1599. <https://doi.org/10.1007/s40262-020-00903-0>
44. Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM (2020) Randomized double-blind clinical trial comparing ultra rapid lispro with Lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. *Diabetes Care* 43(12):2991–2998. <https://doi.org/10.2337/dc19-2550>
45. Loughheed WD, Zinman B, Strack TR et al (1997) Stability of insulin lispro in insulin infusion systems. *Diabetes Care* 20:1061–1065. <https://doi.org/10.2337/diacare.20.7.1061>
46. Mudaliar SR, Lindberg FA, Joyce M et al (1999) Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin. *Diabetes Care* 22:1501–1506. <https://doi.org/10.2337/diacare.22.9.1501>
47. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H (2005) Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. *Exp Clin Endocrinol Diabetes* 113:435–443. <https://doi.org/10.1055/s-2005-865806>
48. Bakhtiani PA, Caputo N, Castle JR et al (2014) A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. *J Diabetes Sci Technol* 9(1):17–23
49. Jacobs PG, El Youssef J, Reddy R et al (2016) Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. *Diabetes Obes Metab* 18(11):1110–1119. <https://doi.org/10.1111/dom.12707>
50. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R (2015) Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump

- therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. *Lancet Diabetes Endo* 3(1):17–26. [https://doi.org/10.1016/S2213-8587\(14\)70226-8](https://doi.org/10.1016/S2213-8587(14)70226-8)
51. Haidar A, Legault L, Matteau-Pelletier L et al (2015) Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. *Lancet Diabetes Endo* 3(8):595–604. [https://doi.org/10.1016/S2213-8587\(15\)00141-2](https://doi.org/10.1016/S2213-8587(15)00141-2)
  52. Haidar A (2019) Insulin-and-glucagon artificial pancreas versus insulin-alone artificial pancreas: a short review. *Diabetes Spectrum* 32(3):215–221. <https://doi.org/10.2337/ds18-0097>
  53. Castle JR, El Youssef J, Wilson LM et al (2018) Randomized outpatient trial of single-and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. *Diabetes Care* 41(7):1471–1477. <https://doi.org/10.2337/dc18-0228>
  54. Blauw H, Keith-Hynes P, Koops R, DeVries JH (2016) A review of safety and design requirements of the artificial pancreas. *Ann Biomed Eng* 44(11):3158–3172. <https://doi.org/10.1007/s10439-016-1679-2>
  55. El-Khatib FH, Balliro C, Hillard MA et al (2016) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. *Lancet* 389(10067):369–380
  56. Jackson MA, Caputo N, Castle JR, David LL, Roberts CT, Ward WK (2012) Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. *Curr Diabetes Rep* 12(6):705–710. <https://doi.org/10.1007/s11892-012-0320-5>
  57. Ribet F, Stemme G, Roxhed N (2017) Ultra-miniaturization of a planar amperometric sensor targeting continuous intradermal glucose monitoring. *Biosensors Bioelectr* 90:577–583. <https://doi.org/10.1016/j.bios.2016.10.007>
  58. Graf A, McAuley SA, Sims C et al (2016) Moving toward a unified platform for insulin delivery and sensing of inputs relevant to an artificial pancreas. *J Diabetes Sci Tech* 1932296816682762
  59. Schade DS, Eaton RP, Friedman JE, Spencer WJ (1980) Normalization of plasma insulin profiles with intraperitoneal insulin in diabetic man. *Diabetologia* 19:35–39. <https://doi.org/10.1007/BF00258308>
  60. Schade DS, Eaton P (1980) The peritoneum—a potential insulin delivery route for a mechanical pancreas. *Diabetes Care* 3(2):229–234. <https://doi.org/10.2337/diacare.3.2.229>
  61. Irsigler K, Kritz H, Hagmüller G et al (1981) Long-term continuous intraperitoneal insulin infusion with an implanted remote-controlled insulin infusion device. *Diabetes* 30(12):1072–1075. <https://doi.org/10.2337/diab.30.12.1072>
  62. Renard E, Boutleau S, Jacques-Apostol D et al (1996) Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility. *Diabetes Care* 19:812–817. <https://doi.org/10.2337/diacare.19.8.812>
  63. Saudek CD, Duckworth WC, Giobbie-Hurder A et al (1996) Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. *JAMA* 276:1322–1327. <https://doi.org/10.1001/jama.1996.03540160044031>
  64. Bally L, Thabit H, Hovorka R (2017) Finding the right route for insulin delivery—an overview of implantable pump therapy. *Expert Opin Drug Deliv* 14(9):1103–1111
  65. Jeandidier N, Boivin S, Sapin R et al (1995) Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. *Diabetologia* 38:577–584. <https://doi.org/10.1007/BF00400727>
  66. Hua QX, Nakagawa SH, Jia W et al (2008) Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications. *J Biol Chem* 283:14703–14716. <https://doi.org/10.1074/jbc.M800313200>
  67. Vinther TN, Normann M, Ribel U et al (2013) Insulin analog with additional disulfide bond has increased stability and preserved activity. *Protein Sci* 22(3):296–305. <https://doi.org/10.1002/pro.2211>
  68. Wu F, Mayer JP, Gelfanov VM, Liu F, DiMarchi RD (2017) Synthesis of four-disulfide insulin analogs via sequential disulfide bond formation. *J Org Chem* 82(7):3506–3512. <https://doi.org/10.1021/acs.joc.6b03078>
  69. Xiong X, Blakely A, Karra P et al (2020) Novel four-disulfide insulin analog with high aggregation stability and potency. *Chem Sci* 11(1):195–200. <https://doi.org/10.1039/C9SC04555D>
  70. Tycko R (2011) Solid-state NMR studies of amyloid fibril structure. *Annu Rev Phys Chem* 62:279–299. <https://doi.org/10.1146/annurev-physchem-032210-103539>
  71. Tycko R, Ishii Y (2003) Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling. *J Am Chem Soc* 125:6606–6607. <https://doi.org/10.1021/ja0342042>
  72. Dobson CM (2003) Protein folding and misfolding. *Nature* 426:884–890. <https://doi.org/10.1038/nature02261>
  73. Wang J, Wang Z, Yu J, Kahkoska AR, Buse JB, Gu Z (2020) Glucose-responsive insulin and delivery systems: innovation and translation. *Adv Mat* 32(13):1902004. <https://doi.org/10.1002/adma.201902004>
  74. Shen D, Yu H, Wang L et al (2020) Recent progress in design and preparation of glucose-responsive insulin delivery systems. *J Control Release* 321:236–258. <https://doi.org/10.1016/j.jconrel.2020.02.014>
  75. Lorand JP, Edwards JO (1959) Polyol complexes and structure of the benzenboronate ion. *J Org Chem* 24(6):769–774. <https://doi.org/10.1021/jo01088a011>
  76. Norrild JC, Eggert H (1995) Evidence for mono-and bisdentate boronate complexes of glucose in the furanose form. Application of  $^{13}\text{C}$ -C coupling constants as a structural probe. *J Am Chem Soc* 117(5):1479–1484. <https://doi.org/10.1021/ja00110a003>
  77. Wang C, Ye Y, Sun W et al (2017) Red blood cells for glucose-responsive insulin delivery. *Adv Mat* 29(18):1606617. <https://doi.org/10.1002/adma.201606617>
  78. Yang J, Wang F, Lu Y et al (2019) Recent advance of erythrocyte-mimicking nanovehicles: from bench to bedside. *J Control Release* 314:81–91. <https://doi.org/10.1016/j.jconrel.2019.10.032>
  79. Brownlee M, Cerami A (1983) Glycosylated insulin complexed to concanavalin A. Biochemical basis for a closed-loop insulin delivery system. *Diabetes* 32(6):499–504. <https://doi.org/10.2337/diab.32.6.499>
  80. Ballerstadt R, Evans C, McNichols R, Gowda A (2006) Concanavalin A for *in vivo* glucose sensing: a biotoxicity review. *Biosens Bioelectron* 22(2):275–284. <https://doi.org/10.1016/j.bios.2006.01.008>
  81. Coutinho A, Larsson EL, Grönvik KO, Andersson J (1979) Studies on T lymphocyte activation II. The target cells for concanavalin A-induced growth factors. *Eur J Immun* 9(8):587–592. <https://doi.org/10.1002/eji.1830090803>
  82. Kamati VV, Gao X, Gao S et al (2002) A glucose-selective fluorescence sensor based on boronic acid-diol recognition. *Bioorg Med Chem Lett* 12(23):3373–3377. [https://doi.org/10.1016/S0960-894X\(02\)00767-9](https://doi.org/10.1016/S0960-894X(02)00767-9)
  83. Fang H, Kaur G, Wang B (2004) Progress in boronic acid-based fluorescent glucose sensors. *J Fluoresc* 14(5):481–489. <https://doi.org/10.1023/B:JOFL.0000039336.51399.3b>
  84. Peters JA (2014) Interactions between boric acid derivatives and saccharides in aqueous media: structures and stabilities of resulting esters. *Coord Chem Rev* 268:1–22. <https://doi.org/10.1016/j.ccr.2014.01.016>

85. Zhao R, Lu Z, Yang J, Zhang L, Li Y, Zhang X (2020) Drug delivery system in the treatment of diabetes mellitus. *Frontiers Bioengin Biotechnol* 8:880
86. Jin X, Zhang X, Wu Z et al (2009) Amphiphilic random glycopolymer based on phenylboronic acid: synthesis, characterization, and potential as glucose-sensitive matrix. *Biomacromol* 10(6):1337–1345. <https://doi.org/10.1021/bm8010006>
87. Wang Y, Huang F, Sun Y, Gao M, Chai Z (2017) Development of shell cross-linked nanoparticles based on boronic acid-related reactions for self-regulated insulin delivery. *J Biomater Sci Polym Ed* 28(1):93–106. <https://doi.org/10.1080/09205063.2016.1246289>
88. Wang H, Yi J, Yu Y, Zhou S (2017) NIR upconversion fluorescence glucose sensing and glucose-responsive insulin release of carbon dot-immobilized hybrid microgels at physiological pH. *Nanoscale* 9(2):509–516. <https://doi.org/10.1039/C6NR07818D>
89. Dong Y, Wang W, Veiseh O et al (2016) Injectable and glucose-responsive hydrogels based on boronic acid–glucose complexation. *Langmuir* 32(34):8743–8747. <https://doi.org/10.1021/acs.langmuir.5b04755>
90. Zion TC, Tsang HH, Ying JY (2003) Glucose-sensitive nanoparticles for controlled insulin delivery. Available from: <https://dspace.mit.edu/handle/1721.1/3783>. Accessed 31 Jan 2021
91. Li X, Fu M, Wu J et al (2017) pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. *Acta Biomater* 51:294–303. <https://doi.org/10.1016/j.actbio.2017.01.016>
92. Anirudhan T, Nair AS, Nair SS (2016) Enzyme coated beta-cyclodextrin for effective adsorption and glucose-responsive closed-loop insulin delivery. *Int J Biol Macromol* 91:818–827. <https://doi.org/10.1016/j.ijbiomac.2016.06.028>
93. Shi D, Ran M, Zhang L et al (2016) Fabrication of biobased polyelectrolyte capsules and their application for glucose-triggered insulin delivery. *ACS Appl Mater Interfaces* 8(22):13688–13697. <https://doi.org/10.1021/acsami.6b02121>
94. Taylor MJ, Chauhan KP, Sahota TS (2020) Gels for constant and smart delivery of insulin. *Brit J Diabetes* 20(1):41–51. <https://doi.org/10.15277/bjd.2020.248>
95. Gu Z, Dang TT, Ma M et al (2013) Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. *ACS Nano* 7(8):6758–6766. <https://doi.org/10.1021/nn401617u>
96. Yesilyurt V, Webber MJ, Appel EA, Godwin C, Langer R, Anderson DG (2016) Injectable self-healing glucose-responsive hydrogels with pH-regulated mechanical properties. *Adv Mater* 28(1):86–91. <https://doi.org/10.1002/adma.201502902>
97. Ito Y, Imanishi Y (1994) Protein device for glucose-sensitive release of insulin. Design and synthesis of a protein device that releases insulin in response to glucose concentration. *Bioconjug Chem* 5(1):84–87. <https://doi.org/10.1021/bc00025a011>
98. Hilgenfeld R, Seipke G, Berchtold H, Owens DR (2014) The evolution of insulin glargine and its continuing contribution to diabetes care. *Drugs* 74(8):911–927. <https://doi.org/10.1007/s40265-014-0226-4>
99. Gillies PS, Figgitt DP, Lamb HM (2000) Insulin glargine. *Drugs* 59(2):253–260. <https://doi.org/10.2165/00003495-200059020-00009>
100. Kashyap N, Steiner SS, Pohl R inventors; Biondell, Inc., assignee. Insulin formulations for insulin release as a function of tissue glucose levels. US patent application 2009/0,175,840 A1. 9 Jul 2009
101. Kaarsholm NC, Lin S, Yan L et al (2018) Engineering glucose responsiveness into insulin. *Diabetes* 67(2):299–308. <https://doi.org/10.2337/db17-0577>
102. Yang R, Wu M, Lin S et al (2018) A glucose-responsive insulin therapy protects animals against hypoglycemia. *JCI Insight* 3(1):e97476. <https://doi.org/10.1172/jci.insight.97476>
103. Yang JF, Gong X, Bakh NA et al (2020) Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin. *Diabetes* 69(8):1815–1826. <https://doi.org/10.2337/db19-0879>
104. Taylor SI, DiMarchi RD (2020) Smarter modeling to enable a smarter insulin. *Diabetes* 69(8):1608–1610. <https://doi.org/10.2337/dbi20-0011>
105. Visser SA, Kandala B, Fancourt C, Krug AW, Cho CR (2020) A model-informed drug discovery and development strategy for the novel glucose-responsive insulin MK-2640 enabled rapid decision making. *Clin Pharm Therap* 107(6):1296–1311. <https://doi.org/10.1002/cpt.1729>
106. Friedman S, Pizer R (1975) Mechanism of the complexation of phenylboronic acid with oxalic acid. Reaction which requires ligand donor atom protonation. *J Am Chem Soc* 97(21):6059–6062. <https://doi.org/10.1021/ja00854a018>
107. Springsteen G, Wang B (2002) A detailed examination of boronic acid–diol complexation. *Tetrahedron* 58(26):5291–5300. [https://doi.org/10.1016/S0040-4020\(02\)00489-1](https://doi.org/10.1016/S0040-4020(02)00489-1)
108. Wu X, Li Z, Chen X-X, Fossey JS, James TD, Jiang Y-B (2013) Selective sensing of saccharides using simple boronic acids and their aggregates. *Chem Soc Rev* 42(20):8032–8048. <https://doi.org/10.1039/c3cs60148j>
109. Hoeg-Jensen T, Havelund S, Markussen J inventors; Novo Nordisk A/S, assignee. Glucose-dependent insulins. US patent 7,317,000 B2. 8 Jan 2008
110. Hoeg-Jensen T, Havelund S, Markussen J, Ostergaard S, Ridderberg S, Balschmidt P, Schaffer L, Jonassen I inventors; Novo Nordisk A/S, assignee. Glucose dependent release of insulin from glucose sensing insulin derivatives. US patent 7,316,999 B2. 8 Jan 2008
111. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribell U (2012) Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharm Res* 29(8):2104–2114. <https://doi.org/10.1007/s11095-012-0739-z>
112. Chou DH-C, Webber MJ, Tang BC et al (2015) Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. *Proc Natl Acad Sci* 112(8):2401–2406. <https://doi.org/10.1073/pnas.1424684112>
113. Wang J, Yu J, Zhang Y et al (2019) Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. *Proc Natl Acad Sci* 116(22):10744–10748. <https://doi.org/10.1073/pnas.1901967116>
114. Jensen KJ, Mannerstedt K, Mishra NK et al (2020) An aldehyde responsive, cleavable linker for glucose responsive Insulins. *Chemistry*. <https://doi.org/10.1002/chem.202004878>
115. Menting JG, Whittaker J, Margetts MB et al (2013) How insulin engages its primary binding site on the insulin receptor. *Nature* 493(7431):241–245. <https://doi.org/10.1038/nature11781>
116. Menting JG, Yang Y, Chan SJ et al (2014) Protective hinge in insulin opens to enable its receptor engagement. *Proc Natl Acad Sci* 111(33):E3395–E3404
117. Scapin G, Dandey VP, Zhang Z et al (2018) Structure of the insulin receptor–insulin complex by single-particle cryo-EM analysis. *Nature* 556(7699):122–125. <https://doi.org/10.1038/nature26153>
118. Weis F, Menting JG, Margetts MB et al (2018) The signalling conformation of the insulin receptor ectodomain. *Nat Commun* 9(1):4420. <https://doi.org/10.1038/s41467-018-06826-6>
119. Weiss M inventor; Case Western Reserve University, assignee. Insulin analogues with a glucose-regulated conformational switch. US patent 10,584,156 B2. 10 Mar 2020
120. Angyal SJ (1984) The composition of reducing sugars in solution. In: Tipson RS, Horton D (eds) *Advances in carbohydrate chemistry and biochemistry*, vol 42. Elsevier, Amsterdam, pp 15–68

121. Bérubé M, Dowlut M, Hall DG (2008) Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: structure and selectivity of complex formation. *J Org Chem* 73(17):6471–6479. <https://doi.org/10.1021/jo800788s>
122. Pal A, Bérubé M, Hall DG (2010) Design, synthesis, and screening of a library of peptidyl bis (boroxoles) as oligosaccharide receptors in water: identification of a receptor for the tumor marker TF-antigen disaccharide. *Angew Chem Int Ed* 49(8):1492–1495. <https://doi.org/10.1002/anie.200906620>
123. Sharma B, Bugga P, Madison LR et al (2016) Bisboronic acids for selective, physiologically relevant direct glucose sensing with surface-enhanced Raman spectroscopy. *J Am Chem Soc* 138(42):13952–13959. <https://doi.org/10.1021/jacs.6b07331>
124. Bian Z, Liu A, Li Y et al (2020) Boronic acid sensors with double recognition sites: a review. *Analyst* 145(3):719–744. <https://doi.org/10.1039/C9AN00741E>
125. Sun X, James TD (2015) Glucose sensing in supramolecular chemistry. *Chem Rev* 115(15):8001–8037. <https://doi.org/10.1021/cr500562m>
126. Davis AP (2020) Biomimetic carbohydrate recognition. *Chem Soc Rev* 49(9):2531–2545. <https://doi.org/10.1039/C9CS00391F>
127. Tromans RA, Samanta SK, Chapman AM, Davis AP (2020) Selective glucose sensing in complex media using a biomimetic receptor. *Chem Sci* 11(12):3223–3227. <https://doi.org/10.1039/C9SC05406E>
128. Brunel FM, Mayer JP, Gelfanov VM et al (2019) A disulfide scan of insulin by [3+ 1] methodology exhibits site-specific influence on bioactivity. *ACS Chem Biol* 14(8):1829–1835. <https://doi.org/10.1021/acscchembio.9b00420>
129. Zaykov AN, Mayer JP, Gelfanov VM, Dimarchi RD (2014) Chemical synthesis of insulin analogs through a novel precursor. *ACS Chem Biol* 9(3):683–691. <https://doi.org/10.1021/cb400792s>
130. Hua QX, Hu SQ, Frank BH et al (1996) Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue. *J Mol Biol* 264:390–403. <https://doi.org/10.1006/jmbi.1996.0648>
131. Hua QX, Xu B, Huang K et al (2009) Enhancing the activity of insulin by stereospecific unfolding. Conformational life cycle of insulin and its evolutionary origins. *J Biol Chem* 284:14586–14596. <https://doi.org/10.1074/jbc.M900085200>
132. Bliss M (2103) The discovery of insulin: the twenty-fifth anniversary edition. University of Chicago Press, Chicago
133. Hovorka R (2011) Closed-loop insulin delivery: from bench to clinical practice. *Nat Rev Endocrinol* 7(7):385–395. <https://doi.org/10.1038/nrendo.2011.32>
134. Jazowski SA, Winn AN (2017) The role of the FDA and regulatory approval of new devices for diabetes care. *Curr Diabetes Rep* 17(6):40
135. Boughton CK, Hovorka R (2019) Is an artificial pancreas (closed-loop system) for type 1 diabetes effective? *Diabet Med* 36(3):279–286. <https://doi.org/10.1111/dme.13816>
136. Beregszászi M, Tubiana-Rufi N, Benali K, Noël M, Bloch J, Czernichow P (1997) Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. *J Pediatr* 131(1):27–33. [https://doi.org/10.1016/S0022-3476\(97\)70121-5](https://doi.org/10.1016/S0022-3476(97)70121-5)
137. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352(9131):837–853. [https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)
138. Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358(24):2560–2572. <https://doi.org/10.1056/NEJMoa0802987>
139. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 360(2):129–139. <https://doi.org/10.1056/NEJMoa0808431>
140. The DCCT Research Group (1991) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. *Am J Med* 90(4):450–459. [https://doi.org/10.1016/0002-9343\(91\)80085-Z](https://doi.org/10.1016/0002-9343(91)80085-Z)
141. The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. *Diabetes* 46(2):271–286. <https://doi.org/10.2337/diab.46.2.271>
142. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358(24):2545–2559. <https://doi.org/10.1056/NEJMoa0802743>
143. Genuth S, Ismail-Beigi F (2012) Clinical implications of the ACCORD trial. *J Clin Endocrinol Metab* 97(1):41–48. <https://doi.org/10.1210/jc.2011-1679>
144. Beran D, Hirsch IB, Yudkin JS (2018) Why are we failing to address the issue of access to insulin? A national and global perspective. *Diabetes Care* 41(6):1125–1131. <https://doi.org/10.2337/dc17-2123>
145. Rege NK, Phillips NFB, Weiss MA (2017) Development of glucose-responsive ‘smart’ insulin systems. *Curr Opin Endocrinol Diabetes Obes* 24(4):267–278. <https://doi.org/10.1097/med.0000000000000345>
146. Tromans RA, Carter TS, Chabanne L et al (2019) A biomimetic receptor for glucose. *Nat Chem* 11(1):52–56. <https://doi.org/10.1038/s41557-018-0155-z>
147. Hua QX, Nakagawa SH, Hu SQ, Jia W, Wang S, Weiss MA (2006) Toward the active conformation of insulin. Stereospecific modulation of a structural switch in the B chain. *J Biol Chem* 281:24900–24909. <https://doi.org/10.1074/jbc.M602691200>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.